Topic Paragraphs
Donate COVID-19 Plasma
If you have fully recovered from COVID-19, you may be able to help patients currently fighting the infection by donating your plasma.
Featured Topics
FDA’s Technology Modernization Action Plan
The plan describes important near-term actions that FDA is taking to modernize use of technology—computer hardware, software, data, and analytics—to advance FDA’s public health mission.
Fostering Drug Competition
Increasing the availability of generic drugs helps to create competition in the marketplace, helping make treatment more affordable and increasing access to healthcare for more patients.
Combating the Opioid Crisis
FDA takes actions to combat prescription opioid abuse.
Recalls, Market Withdrawals, & Safety Alerts
The FDA provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this website
Jul 09
Sundial Herbal Products is Recalling Products Attached Because these Products were Misbranded. The Products are Currently Unapproved Drugs, Recall is Required by the Order
Food & Beverages
Jul 08
Lupin Pharmaceuticals, Inc. Issues Voluntarily Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets, 500mg and 1000mg Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
Drugs
Jul 07
Allergy Alert: KIND Issues Voluntary Recall Due to Undeclared Sesame Seeds in Oats & Honey
Food & Beverages
Paragraph Header
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS
Partnering with the European Union and Global Regulators on COVID-19
The FDA and the European Commission (EC) and its European Medicines Agency (EMA) are collaborating on many fronts as part of our COVID-19 response.
FDA Maintains the Pace of Meeting Its Goals on Applications for Medical Products During the Pandemic
FDA has maintained the same pace of meeting its goals on review of applications for medical products during the pandemic that it has maintained in recent years.
Rare Disease Therapy Development and Access Remain Top FDA Priorities During COVID-19
FDA’s work to advance treatments for rare diseases and helping ensure continuity of care for people with rare diseases remain top priorities during COVID-19.
Recently Published Guidances
Jul 14
Select Updates for Guidance for the Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH)
Medical Devices
Jul 13
Select Updates for Peripheral Vascular Atherectomy Devices - Premarket Notification [510(k)] Submissions
Medical Devices
Jul 10
Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies
Biologics, Drugs